Adeno-associated virus-based gene therapy for inherited disorders

Area of Science:

• Gene therapy
• Viral vector technology
• Molecular medicine

Background:

• Adeno-associated virus (AAV) vectors have demonstrated potential for sustained gene transfer with minimal adverse effects in various animal models.
• Preclinical and early clinical trials have explored AAV vector feasibility for genetic disorders like cystic fibrosis and alpha-1 antitrypsin deficiency.

Purpose of the Study:

• To assess the feasibility and safety of in vivo gene transfer using adeno-associated virus (AAV) vectors.
• To identify limitations of current AAV2 gene therapy vectors.
• To guide the development of next-generation AAV vectors.

Main Methods:

• Review of preclinical and early-phase clinical trial data for AAV-based gene therapy.
• Identification and analysis of limitations associated with AAV2 vectors.
• Development of novel AAV vector strategies utilizing modified capsids and promoters.

Main Results:

• In vivo gene transfer using AAV vectors has been shown to be feasible and relatively safe in tested models.
• Key limitations of existing AAV2 gene therapy vectors have been identified.
• Newer AAV vector designs incorporating mutant/alternative serotypes and enhanced promoters are under development.

Conclusions:

• AAV vectors represent a viable platform for long-term gene therapy.
• Understanding limitations has spurred innovation in AAV vector design.
• Ongoing evaluation of novel AAV vectors is crucial for advancing gene therapy applications.